Immunovant (IMVT) EBT (2018 - 2026)

Immunovant (IMVT) has 9 years of EBT data on file, last reported at -$150.7 million in Q1 2026.

• Quarterly EBT fell 42.35% year-over-year to -$150.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$505.4 million (down 22.39% YoY) and the FY2026 annual result came in at -$505.4 million, down 22.39% from the prior year.
• EBT fell to -$150.7 million in Q1 2026, from -$109.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$40.0 million in Q2 2022 to a low of -$150.7 million in Q1 2026.
• A 5-year average of -$84.4 million and a median of -$75.1 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2023 — EBT advanced 18.0% — and 2024, when it slumped 115.37%.
• Tracing IMVT's EBT over 5 years: stood at -$62.8 million in 2022, then rose by 18.0% to -$51.5 million in 2023, then tumbled by 115.37% to -$111.0 million in 2024, then rose by 1.7% to -$109.1 million in 2025, then plunged by 38.15% to -$150.7 million in 2026.
• The last three EBT figures came in at -$150.7 million (Q1 2026), -$109.1 million (Q4 2025), and -$125.9 million (Q3 2025), per Business Quant data.